5319-43-7

Basic information

• Product Name: 2-[(3-fluorophenyl)amino]acetic acid
• Synonyms: 2-[(3-fluorophenyl)amino]acetic acid
• CAS NO: 5319-43-7
• Molecular Formula: C₈H₈FNO₂
• Molecular Weight: 169.15
• Mol File: 5319-43-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 360.9±27.0 °C(Predicted)
• Appearance: /
• Density: 1.361±0.06 g/cm3(Predicted)
• PKA: 4.15±0.20(Predicted)
• CAS DataBase Reference: 2-[(3-fluorophenyl)amino]acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(3-fluorophenyl)amino]acetic acid(5319-43-7)
• EPA Substance Registry System: 2-[(3-fluorophenyl)amino]acetic acid(5319-43-7)

Safety Data

• Hazardous Substances Data: 5319-43-7(Hazardous Substances Data)

Upstream product

• 372-19-0 meta-fluoroaniline 
• 2573-30-0 N-<3-Fluor-phenyl>-glycin-aethylester 

Downstream Products

• 404-95-5 2-(3-fluoroanilino)ethanol 
• 1227094-23-6 2-(3-fluorophenylamino)-N-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)acetamide 
• 1303559-32-1 N₁-(3-fluorophenyl)-N₂-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)ethane-1,2-diamine 
• 1303559-33-2 N-(2-(3-fluorophenylamino)ethyl)-N-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)-1H-imidazole-1-carboxamide 
• 1303559-24-1 1-(3-fluorophenyl)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)imidazolidin-2-one 

Relevant articles and documents

Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage

So far, there is still no specific drug against COVID-19. Taking compound 1 with anti-EBOV activity as the lead, fifty-four 12N-substituted aloperine derivatives were synthesized and evaluated for the anti-SARS-CoV-2 activities using pseudotyped virus model. Among them, 8a exhibited the most potential effects against both pseudotyped and authentic SARS-CoV-2, as well as SARS-CoV and MERS-CoV, indicating a broad-spectrum anti-coronavirus profile. The mechanism study disclosed that 8a might block a late stage of viral entry, mainly via inhibiting host cathepsin B activity rather than directly targeting cathepsin B protein. Also, 8a could significantly reduce the release of multiple inflammatory cytokines in a time- and dose-dependent manner, such as IL-6, IL-1β, IL-8 and MCP-1, the major contributors to cytokine storm. Therefore, 8a is a promising agent with the advantages of broad-spectrum anti-coronavirus and anti-cytokine effects, thus worthy of further investigation.